CA2538419C - Use of ciclesonide for the treatment of respiratory diseases - Google Patents

Use of ciclesonide for the treatment of respiratory diseases Download PDF

Info

Publication number
CA2538419C
CA2538419C CA2538419A CA2538419A CA2538419C CA 2538419 C CA2538419 C CA 2538419C CA 2538419 A CA2538419 A CA 2538419A CA 2538419 A CA2538419 A CA 2538419A CA 2538419 C CA2538419 C CA 2538419C
Authority
CA
Canada
Prior art keywords
composition
ciclesonide
use according
treating
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2538419A
Other languages
English (en)
French (fr)
Other versions
CA2538419A1 (en
Inventor
Thomas Bethke
Renate Engelstaetter
Wilhelm Wurst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Covis Pharma BV
Original Assignee
Nycomed GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34312429&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2538419(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nycomed GmbH filed Critical Nycomed GmbH
Publication of CA2538419A1 publication Critical patent/CA2538419A1/en
Application granted granted Critical
Publication of CA2538419C publication Critical patent/CA2538419C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
CA2538419A 2003-09-16 2004-09-15 Use of ciclesonide for the treatment of respiratory diseases Expired - Fee Related CA2538419C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50298403P 2003-09-16 2003-09-16
US60/502,984 2003-09-16
PCT/EP2004/052172 WO2005025578A1 (en) 2003-09-16 2004-09-15 Use of ciclesonide for the treatment of respiratory diseases

Publications (2)

Publication Number Publication Date
CA2538419A1 CA2538419A1 (en) 2005-03-24
CA2538419C true CA2538419C (en) 2012-07-03

Family

ID=34312429

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2538419A Expired - Fee Related CA2538419C (en) 2003-09-16 2004-09-15 Use of ciclesonide for the treatment of respiratory diseases

Country Status (11)

Country Link
US (4) US8371292B2 (enExample)
EP (1) EP1670482B2 (enExample)
JP (2) JP5618452B2 (enExample)
AU (1) AU2004271744B2 (enExample)
CA (1) CA2538419C (enExample)
DK (1) DK1670482T4 (enExample)
ES (1) ES2452691T5 (enExample)
HR (1) HRP20140257T4 (enExample)
PL (1) PL1670482T5 (enExample)
PT (1) PT1670482E (enExample)
WO (1) WO2005025578A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2312844T3 (es) * 2002-12-12 2009-03-01 Nycomed Gmbh Medicamento de combinacion de r, r-formoterol y ciclesonida.
WO2005025578A1 (en) * 2003-09-16 2005-03-24 Altana Pharma Ag Use of ciclesonide for the treatment of respiratory diseases
PE20050941A1 (es) 2003-12-16 2005-11-08 Nycomed Gmbh Suspensiones acuosas de ciclesonida para nebulizacion
JP2007524698A (ja) * 2004-02-27 2007-08-30 アルタナ　ファルマ　アクチエンゲゼルシャフト シクレソニドとグリコピロニウムとの組合せ物
JP2007533706A (ja) * 2004-04-20 2007-11-22 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 喫煙患者における呼吸器疾患の治療のためのシクレソニドの使用
EP1904514A2 (en) * 2006-02-08 2008-04-02 Sicor, Inc. Crystalline forms of ciclesonide
MX2010004529A (es) * 2007-10-25 2010-05-10 Merck Frosst Canada Ltd Composiciones de inhalacion que comprenden acido montelukast y un inhibidor de fosfodiesterasa-4 o un corticoesteroide inhalado.
ES2471145T3 (es) * 2009-03-09 2014-06-25 Mikasa Seiyaku Co,. Ltd. Compuesto esteroide
WO2013024070A1 (en) 2011-08-18 2013-02-21 Nycomed Gmbh Pharmaceutical aerosol product for administration by oral or nasal inhalation
ES2706757T3 (es) * 2012-12-21 2019-04-01 Boehringer Ingelheim Vetmedica Gmbh Formulación farmacéutica que comprende ciclesonida
HRP20181980T1 (hr) 2012-12-21 2019-01-25 Boehringer Ingelheim Vetmedica Gmbh Ciklezonid za liječenje dišnih puteva kod konja
WO2015193213A1 (en) 2014-06-18 2015-12-23 Boehringer Ingelheim Vetmedica Gmbh Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses
JP2019513436A (ja) * 2016-03-24 2019-05-30 セルヴィス メディコー アーノルド エ ジョアン ジドゥルカ インコーポレーテッド 上気道に粒子を投与する装置及び方法
RS62040B1 (sr) 2016-06-02 2021-07-30 Abbvie Inc Agonist receptora glukokortikoida i njegovi imunokonjugati
EP3658192B1 (en) 2017-12-01 2021-04-28 AbbVie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
WO2025085662A1 (en) 2023-10-17 2025-04-24 Vanderbilt University Compounds for tocolytic use

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE9716T1 (de) 1980-02-27 1984-10-15 Tate & Lyle Public Limited Company Kristalline glukose und verfahren zu deren herstellung.
US4816445A (en) 1984-06-21 1989-03-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Crystalline alpha-maltose
JP2518646B2 (ja) 1987-05-29 1996-07-24 株式会社 林原生物化学研究所 マルト−ス粉末の製造方法
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
DE407028T1 (de) 1989-05-31 1994-03-17 Fisons Plc Medikament und Inhalationsvorrichtung dafür.
GB8921222D0 (en) 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
IL97065A (en) 1990-02-02 1994-01-25 Fisons Plc Repellent preparations for aerosol
DE4003272A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
US5178866A (en) 1990-03-23 1993-01-12 Alza Corporation Dosage form for delivering drug to the intestine
JPH05505824A (ja) 1990-03-23 1993-08-26 ミネソタ　マイニング　アンド　マニュファクチャリング　カンパニー 所定投与量エアロゾル製剤の製造のための可溶性弗素界面活性剤の使用
GR1001529B (el) 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
US5434304A (en) 1990-09-26 1995-07-18 Aktiebolaget Astra Process for preparing formoterol and related compounds
ATE114112T1 (de) 1990-10-18 1994-12-15 Minnesota Mining & Mfg Aerosolzubereitung, die beclometason 17,21- dipropionat enthält.
US5290539A (en) 1990-12-21 1994-03-01 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US6866839B2 (en) 1991-04-05 2005-03-15 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
US5795564A (en) 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
PT656206E (pt) 1991-06-10 2001-11-30 Schering Corp Formulacoes de aerossois sem clorofluorocarbonetos
IT1250691B (it) 1991-07-22 1995-04-21 Giancarlo Santus Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac.
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
GB9213874D0 (en) 1992-06-30 1992-08-12 Fisons Plc Process to novel medicament form
GB9306703D0 (en) 1993-03-31 1993-05-26 Fisons Plc Inhalation device
CZ287877B6 (cs) 1993-04-02 2001-03-14 Byk Gulden Lomberg Chemische Fabrik Gmbh Prednisolonové deriváty a farmaceutické prostředky s jejich obsahem
US5476411A (en) 1993-07-16 1995-12-19 Henkel Corporation Aqueous composition for wet sanding of dried paint, plastics, and the like
IL111194A (en) 1993-10-08 1998-02-08 Fisons Plc Process for the production of medicament formulations
DE4434629C1 (de) 1994-09-28 1996-06-27 Byk Gulden Lomberg Chem Fab Zusammensetzungen zur Behandlung von IRDS und ARDS
DE19541689A1 (de) 1994-11-14 1996-05-15 Byk Gulden Lomberg Chem Fab Kombinationsarzneimittel
EP1366777B1 (en) 1995-04-14 2005-06-15 SmithKline Beecham Corporation Metered dose inhaler for salmeterol
US5811388A (en) 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
ATE301457T1 (de) 1995-06-12 2005-08-15 Searle & Co Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
US5840917A (en) 1995-09-26 1998-11-24 Takeda Chemical Industries, Ltd. Phosphorylamides, their preparation and use
DE19635498A1 (de) 1996-09-03 1998-03-26 Byk Gulden Lomberg Chem Fab Verfahren zur Epimerenanreicherung
SE9603725D0 (sv) 1996-10-11 1996-10-11 Astra Ab New teatment
US6380222B2 (en) 1996-10-11 2002-04-30 Astrazeneca Ab Use of an H+, K+-atpase inhibitor in the treatment of nasal polyps
FR2754712B1 (fr) 1996-10-17 1999-09-03 Merck Sharp Dohme Chibret Lab Compositions ophtalmiques
US6613795B2 (en) 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
SE9700135D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
US20020111495A1 (en) 1997-04-04 2002-08-15 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
US6120752A (en) 1997-05-21 2000-09-19 3M Innovative Properties Company Medicinal aerosol products containing formulations of ciclesonide and related steroids
GB2329939A (en) 1997-06-26 1999-04-07 Glaxo Group Ltd Self-lubricating valve stem for aerosol containers
US6470894B2 (en) 1997-09-19 2002-10-29 Thione International, Inc. Glutathione, green tea, grape seed extract to neutralize tobacco free radicals
SE9704186D0 (sv) 1997-11-14 1997-11-14 Astra Ab New composition of matter
ATE401312T1 (de) 1997-12-15 2008-08-15 Astellas Pharma Inc Pyrimidin-5-carboxamid-derivate
SE9801368D0 (sv) 1998-04-20 1998-04-20 Astra Ab New use
TWI243687B (en) 1998-04-21 2005-11-21 Teijin Ltd Pharmaceutical composition for application to mucosa
US6264923B1 (en) * 1998-05-13 2001-07-24 3M Innovative Properties Company Medicinal aerosol formulation of ciclesonide and related compounds
US6241969B1 (en) 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
NZ509328A (en) 1998-07-24 2002-11-26 Jago Res A Medicinal aerosol formulations
ATE234604T1 (de) 1998-08-04 2003-04-15 Jago Res Ag Medizinische aerosolformulierungen
WO2000017200A1 (en) 1998-09-23 2000-03-30 Byk Gulden Lomberg Chemische Fabrik Gmbh Tetrahydropyridoethers
CN1150895C (zh) 1998-11-13 2004-05-26 杰格研究股份公司 用于吸入给药的干粉
US6352152B1 (en) 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6397838B1 (en) 1998-12-23 2002-06-04 Battelle Pulmonary Therapeutics, Inc. Pulmonary aerosol delivery device and method
US6124268A (en) 1999-02-17 2000-09-26 Natreon Inc. Natural antioxidant compositions, method for obtaining same and cosmetic, pharmaceutical and nutritional formulations thereof
EP1194244B1 (en) 1999-04-23 2005-12-21 Battelle Memorial Institute Directionally controlled ehd aerosol sprayer
DE60030103T2 (de) 1999-04-23 2007-02-08 Ventaira Pharmaceuticals, Inc., Columbus Elektrostatisches versprühen mit transfer- hoher masse
JP2001048807A (ja) 1999-08-04 2001-02-20 Wakamoto Pharmaceut Co Ltd 難溶性薬物を水に溶解してなる製剤
DE19947234A1 (de) 1999-09-30 2001-04-05 Asta Medica Ag Neue Kombination von Loteprednol und Antihistaminika
AR026072A1 (es) 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica que contiene ciclesonida para aplicacion a la mucosa
AR026073A1 (es) 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica acuosa que contiene ciclesonida
GB0002336D0 (en) 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
GB0009607D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Medical compositions
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
TWI227231B (en) 2000-07-12 2005-02-01 Novartis Ag 4-benzoyl-piperidine derivatives for treating conditions mediated by CCR-3
FI20002177A0 (fi) 2000-10-02 2000-10-02 Orion Yhtymae Oyj Uusi yhdistelmä astman hoitoon
CN1635870A (zh) 2000-10-09 2005-07-06 3M创新有限公司 药用气雾剂制剂
US20020183292A1 (en) 2000-10-31 2002-12-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and corticosteroids
DE10062712A1 (de) * 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
US6528527B2 (en) 2000-11-07 2003-03-04 Merck & Co., Inc. Method of treatment with a combination of a PDE4 inhibitor and a leukotriene antagonist
NZ526564A (en) 2000-12-22 2004-12-24 Glaxo Group Ltd Metered dose inhaler for salmeterol xinafoate
WO2003006310A1 (fr) 2001-07-13 2003-01-23 Tfe Techniques Et Fabrications Electroniques Dispositif destine a indiquer acoustiquement a un plongeur equipe d'un scaphandre la pression de gaz de respiration dans le reservoir et/ou la pression hydrostatique
JP2005508220A (ja) 2001-10-24 2005-03-31 パーリ・ゲーエムベーハー 薬用組成物調製用具
EP1453743B1 (en) 2001-11-17 2008-07-23 Aventis Pharma Limited Pharmaceutical product and method with an adsorbent
WO2003043614A2 (en) 2001-11-19 2003-05-30 Altana Pharma Ag Reversible proton pump inhibitors for the treatment of airway disorders
ITMI20020808A1 (it) 2002-04-17 2003-10-17 Chiesi Farma Spa Procedimento per la preparazione di una sospensione sterile di particelle di beclometasone dipropionato da somministrare per inalazione
BRPI0312377A8 (pt) 2002-07-02 2015-12-15 Altana Pharma Ag Suspensão aquosa estéril contendo ciclesonida
ES2312844T3 (es) 2002-12-12 2009-03-01 Nycomed Gmbh Medicamento de combinacion de r, r-formoterol y ciclesonida.
EP1452179A1 (en) 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
WO2005025578A1 (en) 2003-09-16 2005-03-24 Altana Pharma Ag Use of ciclesonide for the treatment of respiratory diseases

Also Published As

Publication number Publication date
JP5618452B2 (ja) 2014-11-05
ES2452691T3 (es) 2014-04-02
EP1670482B2 (en) 2022-06-29
DK1670482T3 (en) 2014-03-17
US8371292B2 (en) 2013-02-12
DK1670482T4 (da) 2022-08-22
PL1670482T3 (pl) 2014-05-30
ES2452691T5 (es) 2022-09-14
US20190290661A1 (en) 2019-09-26
EP1670482A1 (en) 2006-06-21
AU2004271744A1 (en) 2005-03-24
PL1670482T5 (pl) 2022-10-03
HRP20140257T1 (hr) 2014-04-25
US20220241297A1 (en) 2022-08-04
CA2538419A1 (en) 2005-03-24
HRP20140257T4 (hr) 2022-11-25
AU2004271744B2 (en) 2010-07-29
WO2005025578A1 (en) 2005-03-24
EP1670482B1 (en) 2013-12-25
JP2012197306A (ja) 2012-10-18
PT1670482E (pt) 2014-03-12
US20130143849A1 (en) 2013-06-06
JP2007505829A (ja) 2007-03-15
US20070025923A1 (en) 2007-02-01

Similar Documents

Publication Publication Date Title
US20220241297A1 (en) Use of ciclesonide for the treatment of respiratory diseases
US8313732B2 (en) Formoterol superfine formulation
RU2327450C2 (ru) Фармацевтические продукты и композиции, содержащие специфические антихолинергические средства, агонисты бета-2 и кортикостероиды
US20060293293A1 (en) Salmeterol and ciclesonide combination
ZA200406919B (en) Formoterol superfine formulation
US8088362B2 (en) Salmeterol superfine formulation
WO2000053187A1 (en) New combination of formoterol and mometasone in a pharmaceutical composition for treating respiratory disorders, such as asthma, rhinitis and copd
TWI449523B (zh) 福莫特羅（ｆｏｒｍｏｔｅｒｏｌ）及二丙酸倍氯米松（ｂｅｃｌｏｍｅｔａｓｏｎｅ ｄｉｐｒｏｐｉｏｎａｔｅ）之醫藥噴霧劑配方
EP1720577A2 (en) Ciclesonide and glycopyrronium combination
CA2563556C (en) Use of ciclesonide for the treatment of respiratory diseases in a smoking patient
WO2004110460A1 (en) Formoterol and ciclesonide combination
WO2009090009A1 (en) Pharmaceutical formulation comprising an anticholinergic drug

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190916